Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 17Pancreatic Neoplasms 6Rectal Neoplasms 5Colonic Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Diabetes Mellitus, Insulin-Dependent, 12 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Cancer Metastatic 1Microsatellite Stable Rectal Carcinoma 1Melanoma 1Hemangiosarcoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Hepatocellular 1Carcinoma 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

pembrolizumab 49Nivolumab 21Cisplatin 11Cetuximab 11Carboplatin 10Paclitaxel 8Gemcitabine 8Docetaxel 8atezolizumab 7Ipilimumab 7Cyclophosphamide 7spartalizumab 6durvalumab 6Fluorouracil 6Capecitabine 6fludarabine 5avelumab 5Albumin-Bound Paclitaxel 5cemiplimab 4Trastuzumab 4Taxes 4Oxaliplatin 4Leucovorin 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3tisotumab vedotin 3aldesleukin 3Specimen Handling 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × balstilimab × Gastrointestinal × Clear all
NCT06782555 2025-01-21

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

ImmunoGenesis

Phase 1/2 Recruiting
71 enrolled
GastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡